MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
VolitionRx Limited Operating Income 2011-2026 | VNRX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income VolitionRx Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.7 M | -27 M | -36 M | -31.8 M | -28.3 M | -21.2 M | -16 M | -17.9 M | -14.7 M | -12.4 M | -10 M | -5.95 M | -4.58 M | -4.08 M | -2.61 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.61 M | -36 M | -17 M |
Quarterly Operating Income VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.1 M | -6.3 M | -5.52 M | - | -5.87 M | -6.99 M | -8.38 M | - | -8.65 M | -9.55 M | -9.05 M | - | -7.99 M | -8.1 M | -7.68 M | - | -7.56 M | -5.9 M | -6.09 M | - | -4.5 M | -5.21 M | -5.87 M | - | -4.18 M | -4.15 M | -3.99 M | - | -4.45 M | -4.57 M | -4.63 M | - | -3.88 M | -3.44 M | -3.34 M | - | -3.48 M | -2.98 M | -2.49 M | - | -2.97 M | -2.02 M | -2.35 M | - | -1.76 M | -1.05 M | -1.24 M | - | -926 K | -1.05 M | -908 K | - | -873 K | -931 K | -802 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -802 K | -9.55 M | -4.45 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 17.1 | 0.56 % | $ 181 M |  China |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 21.5 | 3.32 % | $ 1.15 B |  USA |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 114.52 | -0.86 % | $ 34.8 B | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.55 | - | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 24.81 | 1.31 % | $ 689 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.13 | -6.98 % | $ 427 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 112.85 | -4.63 % | $ 9.31 B |  Irlanda |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 135.78 | 7.13 % | $ 21.6 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 85.5 | 1.04 % | $ 5.77 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.8 | 1.05 % | $ 444 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 9.44 | 1.94 % | $ 1.21 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 417.54 | -0.27 % | $ 12 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.41 | 5.77 % | $ 390 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 165.78 | -0.71 % | $ 8.22 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 26.16 | -0.87 % | $ 20 B |  Niderland |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 87.6 | 0.6 % | $ 11 B | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 5.78 | 4.71 % | $ 342 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 2.12 | 7.07 % | $ 9.38 M | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 5.1 | -22.84 % | $ 213 M | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.87 | 0.09 % | $ 2.69 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 469.21 | -2.04 % | $ 177 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 60.4 | 3.34 % | $ 3.61 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 255.84 | -0.37 % | $ 21.3 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 125.65 | 3.54 % | $ 5.88 B | USA |
 |
Natera
NTRA
|
-541 M | $ 207.28 | 0.54 % | $ 20.4 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.53 | 1.38 % | $ 2.07 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Waters Corporation
WAT
|
271 M | $ 307.12 | -0.68 % | $ 18.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 192.67 | -0.79 % | $ 21.4 B | USA |